Overview

A Prospective, Multicentre, Open-label, Single-arm Interventional Study of Bisoprolol (Nerkardou) (Between Low Dose and High Dose) 5 and 10 mg ODF Treatment In Egyptian Patients With Essential Hypertension

Status:
Not yet recruiting

Trial end date:
2024-07-15

Target enrollment:

Participant gender:

Summary

The goal of this prospective, open-label, single-arm interventional study is to Investigate the response, the efficacy of bisoprolol (Nerkardou)-(Oral Dissolvable Film) dosage form in treating patients with hypertension, measure patients' compliance to the (Oral Dissolvable Film) dosage form, especially being easy to carry and easy to use, and identify the onset of action of heart rate reduction.

Phase:

Phase 4

Details

Lead Sponsor:

Genuine Research Center, Egypt

Collaborator:

Nerhadou International for pharmaceutical & Nutraceutical, Egypt